90results about How to "Efficient dosing" patented technology

A medicine ejection device is provided allowing a medicine with a desired droplet diameter to be inhaled at a constant rate. The medicine ejection device has a decision part at which the ejection operating conditions of a medicine ejection part for ejecting the medicine are decided in accordance with at least one of an open-air environment or a state of the medicine during use of the device. The device ejects the medicine according to the ejection operating conditions decided by the decision part.

A biomarker generator system for producing approximately one (1) unit dose of a biomarker. The biomarker generator system includes a small, low-power particle accelerator (“micro-accelerator”) and a radiochemical synthesis subsystem having at least one microreactor and / or microfluidic chip. The micro-accelerator is provided for producing approximately one (1) unit dose of a radioactive substance, such as a substance that emits positrons. The radiochemical synthesis subsystem is provided for receiving the radioactive substance, for receiving at least one reagent, and for synthesizing the approximately one (1) unit dose of a biomarker.

Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).

The present invention generally provides taxane prodrugs comprising at least one taxane joined by hydrolyzable bond(s) to one or more polyethylene glycol oligomer(s) selected from the group consisting of a straight or branched polyethylene glycol oligomer having from 1 to 25 polyethylene glycol units and optionally comprising a salt-forming moiety. The polyethylene glycol oligomer preferably comprises a salt-forming moiety, which is preferably selected from the group consisting of ammonium and carboxylate.

A biomarker generator system for producing approximately one (1) unit dose of a biomarker. The biomarker generator system includes a small, low-power particle accelerator (“micro-accelerator”) and a radiochemical synthesis subsystem having at least one microreactor and / or microfluidic chip. The micro-accelerator is provided for producing approximately one (1) unit dose of a radioactive substance, such as a substance that emits positrons. The radiochemical synthesis subsystem is provided for receiving the radioactive substance, for receiving at least one reagent, and for synthesizing the approximately one (1) unit dose of a biomarker.

A system and method for disinfecting hard surfaces in an area such as a hospital room including a light source emitting UV light and a reflector mounted behind the light source for concentrating and directing the light toward a target. The light source and reflector rotate to direct the concentrated beam around a room, thereby making more efficient use of the energy being emitted.

PCT No. PCT / EP96 / 05025 Sec. 371 Date May 26, 1998 Sec. 102(e) Date May 26, 1998 PCT Filed Nov. 12, 1996 PCT Pub. No. WO97 / 19601 PCT Pub. Date Jun. 5, 1997Fish oil concentrates, having: < / =40% of long chain poly unsaturated fatty acids <20% of saturated fatty acids (C14-C18) <15% oleic acid <12% C16:1-fatty acid and with a weight-ratio: can be obtained by a process involving the following steps subjecting a fish oil to an enzymic conversion removing free fatty acids or esters from conversion-product subjecting product of above to enzymic hydrolysis, using specific lipase or partial glyceride-specific lipase wash and dry product re-esterify dried product.

Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).

The present invention relates to a shaped detergent composition comprising surfactant and cationic fabric softener, characterized in that the composition disintegrates within 5 minutes of been placed in deionised water at 20° C. and that after disintegration, the average particle size of the composition is less than 5 mm, preferably less than 3 mm. The compositions of the present invention can be effectively dosed via the dispensing drawer of standard washing machines and can deliver two or more actives to the wash liquor, even if such actives are incompatible with each other.

Taxane prodrugs comprise a taxane joined by a hydrolyzable bond to one or more oligomers that comprise a polyethylene glycol moiety. The oligomer preferably further comprises a salt-forming moiety.

The present invention is directed to the use of bcl-2 antisense oligomers to treat and prevent bcl-2 related disorders. These disorders include cancers, tumors, carcinomas and cell-proliferative related disorders. In one embodiment of the invention, a bcl-2 antisense oligomer is administered at high doses. The present invention is also directed to a method of preventing or treating a bcl-2 related disorder, in particular cancer, comprising administering a bcl-2 antisense oligomer for short periods of time. The present invention is further drawn to the use of bcl-2 antisense oligomers to increase the sensitivity of a subject to cancer therapeutics. The present invention also relates to pharmaceutical compositions comprising one or more bcl-2 antisense oligomers, which may comprise one or more cancer therapeutic agents.

A method of inhibiting angiogenesis in a mammal is disclosed, which employs a pharmaceutically acceptable composition containing a selective inhibitor of protein kinase CK2 (also known as casein kinase II) enzymatic activity, such as emodin, aloe-emodin, 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB), and 4,5,6,7-tetrabromobenzotriazole (TBB). Also disclosed is a use of a selective inhibitor of protein kinase CK2 enzymatic activity in the manufacture of a medicament for inhibiting angiogenesis. An in vitro method of screening a potential antiangiogenic agent is also disclosed. A kit for the treatment of a disease by inhibiting angiogenesis is disclosed that contains the pharmaceutically acceptable composition containing a selective inhibitor of protein kinase CK2 enzymatic activity.

An automatic injector separately stores liquid and dry components in respective compartments. When the injector is activated, a fluid-directing member between the liquid and dry compartments causes the liquid component to form a vortex as the liquid flows into the dry compartment. This allows the two components to combine more thoroughly and quickly to form a liquid solution that is delivered to an injection site.

The invention relates to novel compositions including an aldosterone antagonist and administered according to a predetermined dosage for treating heart deficiency in non-human mammals.

Disclosed herein are compounds of the formulawherein R1 is independently H or alkyl of 1 to 6 carbons;R2 is optional and is defined as lower alkyl of 1 to 6 carbons, F, Cl, Br, I, CF3, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons;n is an integer of between 0 and 2;o is an integer between 0 and 3;R3 is hydrogen, lower alkyl of 1 to 6 carbons, F, Cl, Br or I;R4 is heteroaryl or (R5)p-heteroaryl where the heteroaryl group is 5-membered or 6-membered and has 1 to 3 heteroatoms selected from the group consisting of O, S, and N;p is an integer having the values of 0–5;R5 is F, Cl, Br, I, NO2, N(R8)2, N(R8)CORO8, N(R8)CON(R8)2, OH, OCOR8, OR8, CN, COOH, COOR8, C1-10 alkyl, fluoro substituted C1-10 alkyl, C2-10 alkenyl having 1 to 3 double bonds, C2-10 alkynyl having 1 to 3 triple bonds, or a (trialkyl)silyl or (trialkyl)silyloxy group where the alkyl groups independently have 1 to 6 carbons;A is (CH2)q where q is 0–5, C3-6 branched alkyl, C3-6 cycloalkyl, C2-6 alkenyl having 1 or 2 double bonds, or C2-6 alkynyl having 1 or 2 triple bonds;B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COORO8, CONR9R10, CH2OH, CH2OR11, CH2OCOR11, CHO, CH(OR12)2, CHOR13O, COR7, CR7(OR12)2, CR7OR13O, or Si(C1-6alkyl)3;R7 is C1-5 alkyl, C3-5 cycloalkyl, or C2-5 alkenyl;R8 is C1-10 alkyl, C1-10 (trimethylsilyl)alkyl, or C5-10 cycloalkyl;R9 and R10 are independently hydrogen, C1-10 alkyl, C5-10 cycloalkyl, phenyl or R12-phenyl;R11 is C1-6 alkyl, phenyl, or R12-phenyl;R12 is C1-6 alkyl; andR13 is divalent alkyl radical of 2–5 carbons.

The invention relates to the fact that a common industrial neutron interrogation screening requirement is that a high throughput rate be accommodated by the screening system. The accumulation of elemental abundance ratio spectral data to minimize statistical uncertainty is a function of the neutron flux passing through the subject. If the subject passes through a neutron beam, with a strictly limited time window for exposure, the flux must be sufficient to accumulate the required statistics. The level of neutron flux necessary may exceed the cost effective limits of the selected neutron source means. Exposure time window dilation is disclosed through a class of system configurations which become practical for reduction to practice by utilization of linear neutron source topology neutron generators. This disclosure is concerned with example embodiments which utilize the length, width, thickness and segmentation of the source emission zone within an appropriate neutron source.

A medicine ejection device is provided allowing a medicine with a desired droplet diameter to be inhaled at a constant rate. The medicine ejection device has a decision part at which the ejection operating conditions of a medicine ejection part for ejecting the medicine are decided in accordance with at least one of an open-air environment or a state of the medicine during use of the device. The device ejects the medicine according to the ejection operating conditions decided by the decision part.

A low-volume biomarker generator for producing ultra-short lived radiopharmaceuticals. The low-volume biomarker generator system includes a low-power cyclotron and a radiochemical synthesis system. The cyclotron of the low-volume biomarker generator is optimized for producing radioisotopes useful in synthesizing radiopharmaceuticals in small quantities down to approximately one (1) unit dose. The cyclotron incorporates permanent magnets in place of electromagnets and / or an improved rf system to reduce the size, power requirements, and weight of the cyclotron. The radiochemical synthesis system of the low-volume biomarker is a small volume system optimized for synthesizing the radiopharmaceutical in small quantities of approximately one (1) unit dose.

The present invention relates to methods for treating diseases and disorders by administering a composition containing the neurotoxic component of a Clostridium botulinum toxin complex, wherein the composition is devoid of any other protein of the Clostridium botulinum toxin complex and wherein the composition is administered at short intervals and / or in high doses.

A system and method for disinfecting hard surfaces in an area such as a hospital room including a light source emitting UV light and a reflector mounted behind the light source for concentrating and directing the light toward a target. The light source and reflector rotate to direct the concentrated beam around a room, thereby making more efficient use of the energy being emitted.

The present invention relates to methods for treating diseases and disorders by administering a composition containing the neurotoxic component of a Clostridium botulinum toxin complex, wherein the composition is devoid of any other protein of the Clostridium botulinum toxin complex and wherein the composition is administered at short intervals and / or in high doses.

The invention relates to the technical field of agriculture, in particular to a pesticide spraying device and method, and particularly discloses an automatic and accurate pesticide feeding device and method for an agricultural UAV. The automatic and accurate pesticide feeding device for the agricultural UAV is characterized in that a first lifting unit is mounted on a trolley; a pesticide conveying box is arranged on the trolley, connected with the UAV and used for feeding pesticide to the UAV; a second lifting unit is connected with the first lifting unit, and a weighing unit is arranged on the second lifting unit; and a controller is used for controlling ascending and descending of the first lifting unit and the second lifting unit, receiving a signal of the weighing unit and controlling the pesticide conveying box to feed the pesticide to the UAV. According to the automatic and accurate pesticide feeding device, the accurate controlling of UAV dosage is achieved, the maximum take-off load is not exceeded when the pesticide is fed to the UAV, or fast and accurate feeding is realized according to a dosage requirement of accurate pesticide application, and the work efficiency of the UAV is improved; and further, the device can perform mobile operation, so that the problem that the carrying is inconvenient when the pesticide is fed to the UAV is solved.

The invention relates to a system and method for enhanced nitrogen removal of sewage through denitrification. The system for enhanced nitrogen removal of sewage through denitrification comprises an anaerobic pool, an anoxic pool, an aerobic pool and a secondary sedimentation pool which are in successive connection. The system further comprises a control system, wherein the control system is connected with an aeration system and a carbon source feeding system; the control system controls the aeration of an aerator so as to allow the DO concentration of the aerobic pool to be 0.5 to 2.9 mg / L andthe ammonia nitrogen concentration of an effluent to be 0.5 to 1.5 mg / L; the carbon source feeding system comprises a nitrate nitrogen on-line monitor and a carbon source feeding device; the nitratenitrogen on-line monitor feeds a nitrate nitrogen concentration back to the control system; and when the nitrate nitrogen concentration of the effluent of the aerobic pool is higher than the set valueof 10 mg / L, the control system controls the carbon source feeding device to feed 5 to 7 units of a carbon source per unit of nitrate into the anoxic pool. According to the invention, intermittent aeration of a sewage treatment plant is realized, so the effluent stably reaches the standard, and energy consumption in aeration is saved; meanwhile, highly-efficient nitrogen removal is realized through accurate chemical feeding in an anoxic area by using the carbon source feeding system according to the nitrate nitrogen concentration of the effluent, so energy consumption in aeration can be saved,and the DO concentration of a reflux liquid is reduced; and the carbon source is accurately added according to the nitrate nitrogen concentration, so highly-efficient denitrification is realized, andthe cost of the carbon source is saved.

In order to control the amount of evaporation of discharged agent droplets and so that a user can inhale agent droplets having a constant diameter regardless of use environment, an inhalation apparatus includes an airflow path communicating with a suction port through which the user inhales an agent, an agent discharging portion configured to discharge an agent supplied to the airflow path, and a humidifier located outside the airflow path and configured to humidify an airflow in the airflow path generated by an inhalation of the user.

An automatic injector separately stores liquid and dry components in respective compartments. When the injector is activated, a fluid-directing member between the liquid and dry compartments causes the liquid component to form a vortex as the liquid flows into the dry compartment. This allows the two components to combine more thoroughly and quickly to form a liquid solution that is delivered to an injection site.

Provided are drug delivery compositions and devices useful for the treatment and / or prevention of cancer and metastatic tumors. For example, a drug delivery device is provided that comprises a biodegradable scaffold carrying one or more anti-cancer therapeutic agents that activate the innate immune system (e.g., STING agonists) and / or the adaptive immune system (e.g., anti-PD-1 antibodies). The compositions and devices may include a cytokine (e.g., IL-15 superagonist). The drug delivery device can be implanted in the void volume of a resected tumor to prevent tumor regrowth and tumor metastasis. Also provided are methods of making the drug delivery compositions and devices as well as kits containing materials to provide the compositions and devices.

The invention relates to new compositions comprising an aldosterone antagonist according to a particular posology for the treatment of heart failure in non-human mammal animals.